Abiraterone 250 mg with prednisone for lowering testosterone in prostate cancer
Tests abiraterone 250 mg with food and prednisone in adults with prostate cancer.
Plain-language title generated from the registry record
Registry title: Castration With Abiraterone 250 mg Without LHRH Analogs or Blockers in Patients With Prostate Cancer Requiring Hormonal Intensification (Multicenter Phase 2)
Key facts
- Where
- Buenos Aires, ArgentinaSee the site
- Phase
- Phase 2
Where in Argentina
- Hospital Carlos A DurandBuenos Aires, ArgentinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- SMED Clinical Research
- Trial code
- NCT07299292
- Record updated
- 23 December 2025
- Original description
HypothesisRead full original descriptionShow less
Castration With Abiraterone 250 mg Without LHRH Analogs or Blockers in Patients With Prostate Cancer Requiring Hormonal Intensification (Multicenter Phase 2)
Hypothesis
The use of Abiraterone 250 mg with food + prednisone, without LHRH analogs or blockers (ADT), achieves castration-level testosterone at 30 days in ≥80-90% of cases.
Inclusion: Age ≥18 years; Histologically confirmed prostate adenocarcinoma; Treated at Hospital Durand (Argentina) or Instituto Oncológico del Oriente Boliviano (Bolivia); Indicated for hormonal intensification (high/very high risk candidates for RT, or mHSPC for doublet/triplet); No prior ADT; ECOG 0-2; adequate hepatic/renal function; K+ ≥3.5 mmol/L; controlled BP.
Exclusion: Concurrent therapy with strongly contraindicated/inducing drugs affecting ABI levels without possibility of adjustment; Hypersensitivity to ABI/prednisone; moderate-severe hepatic impairment; uncontrolled hypertension; refractory hypokalemia.